Regulation 3A(2)
Textual Amendments
1. P is a fully vaccinated amber list arrival if P complies with any of paragraphs 2 to 6.N.I.
2. P complies with this paragraph if P—N.I.
(a)has completed a course of doses of an authorised vaccine with the final dose having been received before the start of the period beginning with the 14th day before the date of P’s arrival in Northern Ireland,
(b)received that course of doses in the United Kingdom or a relevant country,
(c)if the course of doses was received in the United States of America, is ordinarily resident in the United States of America,
(d)is able to provide proof, if required by an immigration officer or the operator of the relevant service on which P travels to Northern Ireland, of meeting the requirement in sub-paragraph (a) through—
(i)the NHS COVID pass, certification issued by the Department of Health, or equivalent from NHS Scotland or NHS Wales,
(ii)the EU Digital COVID Certificate, or
(iii)the Centres for Disease Control and Prevention vaccination card,
(e)is able to provide proof, if required by an immigration officer or the operator of the relevant service on which P travels to Northern Ireland, of meeting the requirement in sub-paragraph (c), and
(f)has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria for reduced isolation and testing requirements.
3. P complies with this paragraph if P—N.I.
(a)has participated, or is participating, in a clinical trial of a vaccine for vaccination against coronavirus carried out in accordance with the requirements of the Medicines for Human Use (Clinical Trials) Regulations 2004,
(b)is able to provide proof of such participation, if required by an immigration officer or the operator of the relevant service on which P travels to Northern Ireland, and
(c)has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria for reduced isolation and testing requirements.
4. P complies with this paragraph if P—N.I.
(a)has participated, or is participating, in a clinical trial regulated in the United States of America by the Food and Drugs Administration of a vaccine for vaccination against coronavirus,
(b)is able, if required by an immigration officer or the operator of the relevant service on which P travels to Northern Ireland, to provide proof of such participation through the Centres for Disease Control and Prevention vaccination card,
(c)has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria for reduced isolation and testing requirements, and
(d)is ordinarily resident in the United States of America and is able to provide proof of that residence, if required by an immigration officer or the operator of the relevant service on which P travels to Northern Ireland.
5. P complies with this paragraph if P is—N.I.
(a)under the age of 18 years upon arrival in Northern Ireland, and
(b)ordinarily resident in the United Kingdom or a relevant country.
6. P complies with this paragraph if P is either—N.I.
(a)a person who—
(i)has completed a course of doses of a vaccine under the United Kingdom vaccine roll-out overseas, with the final dose having been received before the start of the period beginning with the 14th day before the date of their arrival in Northern Ireland,
(ii)is able to provide proof, if required by an immigration officer or the operator of the relevant service on which P travels to Northern Ireland, of meeting the requirements in paragraph (i), and
(iii)has declared on the Passenger Locator Form that P meets the COVID-19 vaccination eligibility criteria for reduced isolation and testing requirements, or
(b)a dependent of a person of the description in any of paragraphs (a) to (c) of the definition of “United Kingdom vaccine roll-out overseas” and is under the age of 18 years upon arrival in Northern Ireland.
7. For the purposes of paragraphs 2 and 6, P has completed a course of doses if P has received the complete course of doses specified—N.I.
(a)in the summary of product characteristics approved as part of the marketing authorisation for the authorised vaccine, or
(b)in the instructions for usage approved as part of the authorisation by the licensing authority on a temporary basis under regulation 174 (supply in response to spread of pathogenic agents etc.) of the Human Medicines Regulations 2012 for the authorised vaccine.
8. For the purposes of paragraph 6, where P has received a dose of an authorised vaccine in the United Kingdom and a dose of a vaccine under the United Kingdom vaccine roll-out overseas, P is deemed to have received a course of doses of a vaccine under the United Kingdom vaccine roll-out overseas.N.I.
9. For the purposes of this Schedule a child is to be treated as making a declaration on a Passenger Locator Form, and providing any proof required, if that declaration is made, and the proof provided, by a person who is travelling with and has responsibility for that child.N.I.
10. In this Schedule—N.I.
“authorised vaccine” means a medicinal product for vaccination against coronavirus authorised—
in relation to doses received in the United Kingdom—
for supply in the United Kingdom in accordance with a marketing authorisation, or
by the licensing authority on a temporary basis under regulation 174 of the Human Medicines Regulations 2012;
in relation to doses received in a relevant country, for supply in that country following evaluation by the relevant regulator for the country,
“clinical trial” has the meaning given in regulation 2(1) of the Medicines for Human Use (Clinical Trials) Regulations 2004,
“Crown servant” has the meaning given in section 12(1)(a) to (e) of the Official Secrets Act 1989,
“government contractor” has the meaning given in section 12(2) of the Official Secrets Act 1989,
“the licensing authority” has the meaning given in regulation 6(2) (the licensing authority and the Ministers) of the Human Medicines Regulations 2012,
“marketing authorisation”—
in relation to a vaccine authorised for supply in the United Kingdom or in a member State, has the meaning given in regulation 8(1) (general interpretation) of the Human Medicines Regulations 2012,
in relation to a vaccine authorised for supply in a relevant country other than a member State, means a marketing authorisation granted by the relevant regulator for the country,
“medicinal product” has the meaning given in regulation 2 (medicinal products) of the Human Medicines Regulations 2012,
“NHS COVID pass” means the COVID-19 records on the NHS smartphone app developed and operated by the Secretary of State, through the website at NHS.uk or a COVID-19 post vaccination letter obtained from the NHS,
“NHS” means the health service continued under section 1(1) of the National Health Service Act 2006,
“NHS Scotland” means the health service continued under section 1(1) of the National Health Service (Scotland) Act 1978,
“NHS Wales” means the health service continued under section 1(1) of the National Health Service (Wales) Act 2006,
“relevant country” means a country listed in the first column of the table in paragraph 11,
“relevant regulator”, in relation to a relevant country, means the regulator identified in the corresponding row of the second column of the table in paragraph 11, and a reference to a regulator in that table is a reference to the regulatory authority of that name designated as a Stringent Regulatory Authority by the World Health Organization pursuant to the operation of the COVAX Facility,
“relevant service” means a commercial transport service carrying passengers to Northern Ireland from outside the common travel area,
“United Kingdom vaccine roll-out overseas” means the administration of vaccination against coronavirus to—
Crown servants, government contractors or other personnel posted or based overseas and their dependants under the scheme known as the Foreign, Commonwealth and Development Office staff COVID-19 vaccination programme;
residents of the British overseas territories, the Channel Islands and the Isle of Man, as part of a programme agreed in the overseas territory, any of the Channel Islands, or the Isle of Man with the United Kingdom government; or
military or civilian personnel, government contractors and their dependants at a military posting overseas, including the British overseas territories, the Channel Islands and the Isle of Man, under the vaccination scheme provided or approved by the UK Defence Medical Services.
11. The table referred to in the definitions of “relevant country” and “relevant regulator” follows—N.I.
| Relevant country | Relevant regulator |
|---|---|
| a member State | European Medicines Agency |
| Andorra | European Medicines Agency |
| Iceland | European Medicines Agency |
| Lichtenstein | European Medicines Agency |
| Monaco | European Medicines Agency |
| Norway | European Medicines Agency |
| San Marino | European Medicines Agency |
| Switzerland | Swissmedic |
| the United States of America | United States Food and Drug Administration |
| Vatican City State | European Medicines Agency] |